Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
352
-
Total 13F shares, excl. options
-
93.9M
-
Shares change
-
-2.54M
-
Total reported value, excl. options
-
$6.89B
-
Value change
-
-$164M
-
Put/Call ratio
-
0.45
-
Number of buys
-
173
-
Number of sells
-
-186
-
Price
-
$73.17
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2024
432 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2024.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 352 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 93.9M shares
of 108M outstanding shares and own 87.14% of the company stock.
Largest 10 shareholders include FMR LLC (11.1M shares), VANGUARD GROUP INC (9.63M shares), BlackRock, Inc. (6.22M shares), JPMORGAN CHASE & CO (5.29M shares), WASATCH ADVISORS LP (3.85M shares), NORGES BANK (3.2M shares), Avoro Capital Advisors LLC (3.05M shares), Invesco Ltd. (2.99M shares), Bellevue Group AG (2.49M shares), and STATE STREET CORP (1.86M shares).
This table shows the top 352 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.